ASX ANNOUNCEMENT

New Study Reports Superior Clinical Outcomes Utilising L-Dex®

Brisbane, Australia and Carlsbad, Calif.- ImpediMed Limited (ASX: IPD) a global provider of medical technology to non-invasively measure, monitor and manage fluid status and body composition, is pleased to announce results from an independent clinical study using L-Dex® for early detection of subclinical lymphoedema.

In a retrospective analysis published today on-line and in a forthcoming issue of the journal Breast Cancer Research and Treatment, Dr David I Kaufman of Bethpage, NY sought to examine the impact of a prospective surveillance protocol utilising bioimpedance spectroscopy (BIS) to detect breast cancer-related lymphoedema (BCRL) at a sub-clinical, reversible stage.

206 consecutive patients in his clinic were prospectively monitored with L-Dex®, including 30 at high-risk for developing lymphedema who had undergone axillary lymph node dissection (ALND). Overall, 9.8% of patients had an abnormally elevated L-Dex score, indicative of sub-clinical disease, at some point during their follow up. That number increased to 23% for ALND patients. Early intervention consisted of a four-week regimen of an over-the-counter compression sleeve to prevent disease progression to a clinical and irreversible stage. None of the patients undergoing early intervention required complete decongestive physiotherapy (CDP) for chronic, clinically detectable lymphoedema.

"This study reported dramatically lower rates of this chronic and irreversible affliction than have been reported in contemporary studies where patients have not been prospectively evaluated for the development of BCRL," commented Richard Carreon, Managing Director and CEO of ImpediMed. "This new data adds to the mounting body of peer-reviewed evidence supporting the positive clinical outcomes of prospective surveillance using L-Dex in limiting this extremely debilitating and lifelong morbidity."

David I Kaufman, M.D., FACS, Adjunct Professor of Surgery at New York University Medical Center and Assistant Professor of Surgery at Hofstra Northwell School of Medicine, who is a breast cancer surgeon and author of the study remarked, "It only takes one patient to develop chronic breast cancer-related lymphoedema to want to prevent it from ever happening again. The L-Dex technology has provided me with the tools necessary to prevent this dreadful complication from happening. This scientific validation of what I had previously believed to be true through my clinical experience, strengthens my resolve to offer this simple, accurate, and readily available surveillance tool to my patients."

The publication can be accessed on-line at: https://link.springer.com/article/10.1007/s10549-017-4451-x

Richard Carreon
Managing Director & CEO
For further information, contact:
Richard Carreon, ImpediMed Managing Director & CEO
Morten Vigeland, ImpediMed CFO
T: +1 (760) 585-2100

Media Contact:
Kyahn Williamson, WE Buchan
T: +61 3 9866 4722
E: kwilliamson@buchanwe.com.au

About ImpediMed
Founded and headquartered in Brisbane, Australia with U.S. offices in Carlsbad, Calif. and Bloomington, Minn., and a European office in Thessaloniki, Greece, ImpediMed is the world leader in the design and manufacture of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of tissue composition and fluid status.
ImpediMed was the first company to receive FDA clearance in the U.S. to aid healthcare professionals to clinically assess unilateral lymphoedema of the arm and leg in women and the leg in men, for its L-Dex® device. In addition, ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZOTM, sold in select markets globally.

For more information, visit www.impedimed.com.